StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

Investment analysts at StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a report released on Tuesday. The brokerage set a “hold” rating on the stock.

Catalent Price Performance

Shares of NYSE CTLT opened at $63.48 on Tuesday. The firm has a market cap of $11.52 billion, a PE ratio of -28.09, a PEG ratio of 2.69 and a beta of 1.15. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. Catalent has a 1-year low of $41.15 and a 1-year high of $63.50. The company has a fifty day moving average price of $62.87 and a 200 day moving average price of $60.74.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the company earned ($0.10) earnings per share. The company’s quarterly revenue was up 4.2% on a year-over-year basis. Research analysts predict that Catalent will post 0.78 earnings per share for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. This represents a 20.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Bank of Montreal Can increased its holdings in shares of Catalent by 181.5% during the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after purchasing an additional 1,169,044 shares during the period. National Bank of Canada FI boosted its position in Catalent by 300.0% in the third quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock valued at $88,481,000 after buying an additional 1,095,578 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its position in Catalent by 166.5% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock valued at $83,733,000 after buying an additional 863,624 shares in the last quarter. ING Groep NV boosted its position in Catalent by 162.5% in the third quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock valued at $68,475,000 after buying an additional 699,851 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of Catalent during the third quarter worth $39,082,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.